immunotherapy / Risk Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱

Features:

Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers

PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class	Example Agents	Primary Target	Core Mechanism	Interaction Considerations	Net Effect
PD-1 inhibitors	Nivolumab, Pembrolizumab	PD-1 receptor on T cells	Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity	High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk	↑ Anti-tumor immune activation
PD-L1 inhibitors	Atezolizumab, Durvalumab	PD-L1 on tumor/immune cells	Prevents PD-L1 from engaging PD-1 → enhances T-cell response	Similar immune-related adverse event (irAE) profile as PD-1 inhibitors	↑ Immune activation
CTLA-4 inhibitors	Ipilimumab	CTLA-4 checkpoint	Enhances early T-cell priming in lymph nodes	Higher autoimmune toxicity risk vs PD-1 class	↑ T-cell priming
CAR-T therapy	CD19 CAR-T products	Tumor antigen (e.g., CD19)	Genetically engineered T cells directly target tumor cells	Risk of cytokine release syndrome (CRS) and neurotoxicity	Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint)	Trastuzumab, Rituximab	Specific tumor antigens	Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade	Combination with chemo common; immune activation depends on Fc engagement	Targeted immune-mediated killing
Cytokine therapy	IL-2, IFN-α	Immune activation pathways	Stimulates T-cell and NK cell proliferation	High systemic toxicity; rarely used now vs checkpoint inhibitors	Broad immune stimulation
Cancer vaccines	mRNA or peptide-based	Tumor antigens	Induces tumor-specific immune memory	Often combined with checkpoint blockade	Adaptive immune priming
Bispecific T-cell engagers	Blinatumomab	CD3 + tumor antigen	Bridges T cells directly to tumor cells	CRS risk; continuous infusion in some protocols	Direct T-cell redirection

Risk, Risk: Click to Expand ⟱

Source:

Type:

Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.

Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral


CRIS  Exposure / Compound  Evidence  Cancers  Notes


-5  Exercise (overall)
VStrong Hum  BC, CRC, Endo, PCa, Liv
↓insulin/IGF-1, ↓inflammation, ↑immune surveillance, ↓hormones



-5  Aerobic + resistance  VStrong Hum  Broad inc + mort
Best overall exercise synergy



-4  Aerobic exercise (mod–vig)  VStrong Hum  BC, CRC, Endo
Dose–response; ↓visceral fat



-4  Resistance training (alone)  Strong Hum  BC, CRC
↑insulin sensitivity; ↑lean mass



-3  High-intensity interval training  Mod–Strong Hum  BC, CRC
↑AMPK; ↑mitochondrial function; adherence matters



-2  NEAT / low-intensity activity  Moderate Hum  CRC
↓sedentary harm



-5  Cruciferous vegetable pattern  Strong Hum  Lung, CRC, BC, PCa
↑NRF2, ↓CYP1; ITC synergy



-5  Sunlight exposure (physiologic)  Strong Hum  CRC, BC, PCa
↑circadian alignment, ↑immune effects beyond vitamin D



-4  Fasting (metabolic pattern)
Strong Mech + Hum  BC, CRC, PCa 
↓IGF-1, ↓mTOR, ↑autophagy



-4  Curcumin
Hum + Pre  GI, BC, PCa
↓NF-κB, ↓STAT3



-4  Sulforaphane
Hum + Pre  Lung, CRC, BC
↑NRF2, ↓HDAC



-4  PEITC
Hum + Pre  Lung, CRC, PCa
↓CYP1A2, ↑apoptosis



-4  EGCG (tea matrix)
Strong Hum  GI, PCa, BC
↓angiogenesis; tea matrix superior to extract



-4  Lycopene
Strong Hum  PCa
↓oxidative DNA damage



-4  Apigenin
Pre + Diet Hum  BC, PCa, CRC 
↓PI3K-AKT, ↑p53



-4  Luteolin
Pre + Diet Hum  Lung, CRC, BC 
↓STAT3, ↓EMT



-4  Kaempferol
Diet Hum  Ov, Panc, Lung
↓VEGF, ↑apoptosis



-4  Fisetin
Pre + Early Hum  CRC, PCa, Mel
↓mTOR; senolytic activity



-4  Ellagic acid → Urolithin A
Hum (microbiome)  CRC, PCa, BC
↑mitophagy, ↓ER/AR signaling



-3  Omega-3 (EPA/DHA)
Strong Hum  CRC, BC
↓inflammation, ↓COX-2



-3  Vitamin D3 (supp)
Obs + RCT  CRC, BC
U-shaped response; ↓proliferation



-3  Garlic (allicin)
Mod Hum  GI
↓inflammation, ↓H. pylori



-3  Mushroom beta-glucans
Hum adjunct  GI, BC
↑NK cells, ↑immune surveillance



-3  Melatonin
Hum + Mech  BC, PCa
↓estrogen signaling, ↑circadian regulation



-3  Coffee (whole)
Strong Hum  Liv, Endo
↓fibrosis, ↓inflammation



-2  Quercetin
Limited Hum  Lung, CRC
Senolytic; ↓PI3K signaling



-2  Resveratrol
Limited Hum  CRC, BC
↓NF-κB; low bioavailability



-2  I3C / DIM
Mod Hum  BC, Cerv
↑2-OH estrogen, ↓ER signaling



-2  Thymoquinone
Early Hum  BC, CRC
↑apoptosis, ↓NF-κB



-2  Beta-carotene (food)
Hum  Lung
Antioxidant only in whole-food context



-1  Vitamin K2 (MK-4/7)
Limited Hum  Liv, PCa
↓proliferation, ↑differentiation



-1  Boron
Obs  PCa, Lung
↓inflammation; hormone modulation



0  Vitamin C (oral)
Strong Hum  —
Neutral overall effect



0  Genistein (soy)
Strong Hum  BC, PCa
Timing-dependent effects



0  Selenium (diet)
Mixed Hum  PCa
Narrow therapeutic window



0  Capsaicin
Mixed  Gastric
Dose-dependent effects



+2  Vitamin E (alpha only)
Strong RCT  PCa
Increased risk signal



+2  Green tea extract (high-dose)
Case reports  Liv
Hepatotoxicity reported



+4  Beta-carotene (supplement)
Strong RCT  Lung (smokers)
Increased lung cancer risk in smokers



+5  Alcohol (ethanol)
Strong Hum  BC, Liv, Eso
Linear increase in cancer risk




Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use

Scientific Papers found: Click to Expand⟱

5628-

Bif,

immuno,

Bifidobacterium modulation of tumor immunotherapy and its mechanism

Review,

Var,

Imm↑, Risk↓, GutMicro↑, AntiTum↑, OS↑, selectivity↑, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes ⓘ

AntiTum↑, 1, OS↑, 1, Risk↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Risk, Risk

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

immunotherapy / Risk Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Home Page